RIBOLDI ILARIA

Cavaleri, D., Riboldi, I., Crocamo, C., Paglia, G., Carrà, G., Bartoli, F. (2024). Evidence from preclinical and clinical metabolomics studies on the antidepressant effects of ketamine and esketamine. NEUROSCIENCE LETTERS, 831(14 May 2024) [10.1016/j.neulet.2024.137791]. Detail

Riboldi, I., Carrà, G. (2024). Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges. ALPHA PSYCHIATRY, 25(3), 312-322 [10.5152/alphapsychiatry.2024.241464]. Detail

Riboldi, I., Calabrese, A., Piacenti, S., Capogrosso, C., Paioni, S., Bartoli, F., et al. (2024). Understanding University Students' Perspectives towards Digital Tools for Mental Health Support: A Cross-country Study. CLINICAL PRACTICE AND EPIDEMIOLOGY IN MENTAL HEALTH, 20(1) [10.2174/0117450179271467231231060255]. Detail

Bartoli, F., Cavaleri, D., Riboldi, I., Crocamo, C., de Filippis, R., Callegher, R., et al. (2024). The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project- Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol. ALPHA PSYCHIATRY, 25(4), 555-560 [10.5152/alphapsychiatry.2024.241549]. Detail

Brittlebank, A., De Picker, L., Krysta, K., Seker, A., Riboldi, I., Hanon, C., et al. (2024). Benchmarking Psychiatry in Europe and beyond: The European Board Exam of Psychiatry. EUROPEAN PSYCHIATRY, 67(1) [10.1192/j.eurpsy.2024.1746]. Detail